

# Victor A Chow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3971072/publications.pdf>

Version: 2024-02-01

15  
papers

268  
citations

1478505

6  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

543  
citing authors

#	ARTICLE	IF	CITATIONS
1	Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 132, 777-781.	1.4	105
2	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213.	4.1	92
3	Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. <i>American Journal of Hematology</i> , 2019, 94, E117-E116.	4.1	19
4	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 4869-4872.	5.2	12
5	Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1247-1252.	2.0	7
6	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	4.1	7
7	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 57.e1-57.e8.	1.2	7
8	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
9	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 37-45.	5.2	3
10	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013, 2, 26-28.	0.4	2
11	Where does transplant fit in the age of targeted therapies?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 287-293.	2.5	2
12	Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. <i>British Journal of Haematology</i> , 2020, 190, e332-e335.	2.5	2
13	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1-2.	1.4	2
14	Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL. <i>Blood</i> , 2018, 132, 2911-2911.	1.4	1
15	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 0, 1-5.	1.3	0